Literature DB >> 11137562

Aberrant expression and localization of the cytoskeleton-binding pp52 (LSP1) protein in hairy cell leukemia.

E K Miyoshi1, P L Stewart, P W Kincade, M B Lee, A A Thompson, R Wall.   

Abstract

Non-retractable cell surface projections and cytoskeleton-mediated functional defects are distinguishing features of both hairy cell leukemia (HCL) and neutrophil actin dysfunction (NAD). These defects in NAD neutrophils are attributed to moderate over-expression of pp52 (LSP1), the F-actin-binding, leukocyte-specific phosphoprotein. Here we report that pp52 is similarly elevated in HCL patient PBMCs. Established HCL cell lines exhibited characteristic morphological features like those of fresh HCL cells and showed elevated pp52 levels. The excess pp52 in these HCL cell lines was selectively associated with the F-actin-rich cytoskeletal arrays in surface projections. Treatments producing radical changes in HCL cell shape also altered pp52 expression and intracellular distribution. Alpha interferon (IFNalpha, used to treat HCL) reduced pp52 levels, normalized intracellular pp52 distribution and reverted HCL cells to rounded B cell morphology. Phorbol ester stimulation rapidly generated hyper-phosphorylated pp52 isoforms which translocated from the cytoskeleton to the cytosol prior to the further elongation of surface spikes. This indicates a direct role for phosphorylation in controlling pp52 interactions with the cytoskeleton. Overall, these findings strongly suggest that elevated pp52 expression and/or selective cytoskeletal association contributes to the distinctive morphology of HCL cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137562     DOI: 10.1016/s0145-2126(00)00079-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells.

Authors:  Benjamin Chaigne-Delalande; Lynda Deuve; Edith Reuzeau; Caroline Basoni; David Lafarge; Christine Varon; Florence Tatin; Guerric Anies; Richard Garand; Ijsbrand Kramer; Elisabeth Génot
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

Review 3.  Leukocyte-specific protein 1 (LSP1): a regulator of leukocyte emigration in inflammation.

Authors:  Jenny Jongstra-Bilen; Jan Jongstra
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 5.  Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies.

Authors:  Deepak Narayanan Iyer; Omar Faruq; Lun Zhang; Nasrin Rastgoo; Aijun Liu; Hong Chang
Journal:  Biomark Res       Date:  2021-05-06

6.  Crucial role for the LSP1-myosin1e bimolecular complex in the regulation of Fcγ receptor-driven phagocytosis.

Authors:  Sebastian Maxeiner; Nian Shi; Carmen Schalla; Guelcan Aydin; Mareike Hoss; Simon Vogel; Martin Zenke; Antonio S Sechi
Journal:  Mol Biol Cell       Date:  2015-02-25       Impact factor: 4.138

7.  Temporal regulation of Lsp1 O-GlcNAcylation and phosphorylation during apoptosis of activated B cells.

Authors:  Jung-Lin Wu; Hsin-Yi Wu; Dong-Yan Tsai; Ming-Feng Chiang; Yi-Ju Chen; Shijay Gao; Chun-Cheng Lin; Chun-Hung Lin; Kay-Hooi Khoo; Yu-Ju Chen; Kuo-I Lin
Journal:  Nat Commun       Date:  2016-08-24       Impact factor: 14.919

8.  Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.

Authors:  Katia Basso; Arcangelo Liso; Enrico Tiacci; Roberta Benedetti; Alessandro Pulsoni; Robin Foa; Francesco Di Raimondo; Achille Ambrosetti; Andrea Califano; Ulf Klein; Riccardo Dalla Favera; Brunangelo Falini
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.